Equine Botulinum Neurotoxin G Immune FAB2
- Generic Name
- Equine Botulinum Neurotoxin G Immune FAB2
- Brand Names
- BAT
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 943578J0XG
- Background
Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and p...
- Indication
Equine Botulinum Neurotoxin G Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype G in adults and pediatric patients [FDA Label].
- Associated Conditions
- Symptomatic Botulism, Symptomatic Botulism caused by Clostridium botulinum serotype G
- Associated Therapies
- -
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 207
- Registration Number
- NCT02577926
- Locations
- 🇩🇪
Universitätsklinikum Ulm Klinik für Innere Medizin III, Ulm, Baden-Württemberg, Germany
🇩🇪Rems-Murr Klinikum Winnenden, Winnenden, Baden-Württemberg, Germany
🇩🇪Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie, Mannheim, Baden-Württemberg, Germany
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 162
- Registration Number
- NCT02055183
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.